Show summary Hide summary
Bank of America upgraded UNH stock to Buy from Neutral on June 4, raising its price target to $450 per share from $420, citing improving medical cost trends and favorable earnings setup for the second quarter. Analyst Kevin Fischbeck pointed to strengthening utilization data as evidence that the healthcare giant’s margin recovery is on track.
Quick Facts
- Price target raised to $450 from $420 — a 7.1% upside from the previous target
- Upgrade date: June 4, 2026 — Bank of America moved UNH from Neutral to Buy
- New target based on 21.4x 2027 earnings estimates — BofA now above consensus for both 2026 and 2027
- UnitedHealth serves 51 million members globally — the nation’s largest publicly traded managed care company
What Drove the Upgrade
Bank of America’s upgrade reflects a shift in confidence around UnitedHealth’s cost structure. The firm highlighted improving medical cost trends, with incoming data on utilization patterns suggesting that strong first-quarter results weren’t solely driven by weak flu activity or weather-related factors. Fischbeck noted that the company’s bellwether status in the managed care industry means a sustained improvement in its trends could trigger broader strength across the sector.
BofA cited three key data points: its proprietary trend tracker, company commentary at a recent industry conference, and comments from Ardent Health on weak April and May utilization. These signals collectively suggest that cost moderation is extending beyond Q1 into the second quarter, setting up what the bank calls a “favorable 2Q earnings setup.”
Invest in education: Haslams give $130M to University of Tennessee in Knoxville
Energy prices could surge: Exxon says shareholders approved exit from a Democratic state
Earnings Power and Margin Recovery
UnitedHealth’s Q1 2026 results already beat expectations, with earnings per share of 7.23 versus an estimate of 6.60 — a 9.52% surprise. BofA argues that the company’s true earnings power is approximately 50% above its 2026 guidance, suggesting significant upside if utilization trends continue to moderate. The firm projects that if UnitedHealth achieves its stated target margins by 2028, the company could deliver earnings north of $26 per share, roughly 5-10% above current Wall Street consensus.
This margin recovery thesis rests on the premise that lower utilization — fewer medical claims — will flow through to the bottom line as UnitedHealth retains pricing power. The company has already taken rate actions to improve its medical cost ratio, and BofA sees continued room for improvement.
Risks and the Road Ahead
BofA acknowledged medium-term headwinds, chiefly 2028 Medicare Advantage star ratings and potential regulatory rate pressure. However, the firm believes that sustained margin recovery would significantly reduce the impact of any rate pressure, since the company would have a larger earnings buffer. The upgraded outlook assumes that the favorable utilization environment persists through the second quarter and beyond, which remains subject to seasonal and epidemiological shifts.
The upgrade reflects a broader confidence in UNH stock‘s ability to compound earnings growth over the next two years, supported by both operational improvements and the company’s scale advantage as a 51-million-member healthcare giant.
Sources
- Investing.com — Bank of America upgrade announcement and analyst commentary from Kevin Fischbeck
- 24/7 Wall St. — Confirmation of UNH upgrade in Thursday analyst calls roundup
- Yahoo Finance — UnitedHealth stock data, analyst ratings, Q1 2026 earnings surprise, and company overview
